PMID- 37286922
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230706
IS  - 2193-8229 (Print)
IS  - 2193-6382 (Electronic)
IS  - 2193-6382 (Linking)
VI  - 12
IP  - 6
DP  - 2023 Jun
TI  - Thalidomide for Recurrence of Symptoms following HIV-Associated Cryptococcal 
      Meningitis.
PG  - 1667-1675
LID - 10.1007/s40121-023-00817-x [doi]
AB  - INTRODUCTION: Cryptococcal meningitis (CM) is a serious and fatal fungal 
      infection that affects individuals infected with human immunodeficiency virus 
      (HIV). Despite treatment, recurrence of symptoms is common and could lead to poor 
      outcomes. Corticosteroids are not always useful in treating symptom recurrence 
      following HIV/CM; thus, alternative therapy is needed. Thalidomide has been 
      reported to be effective in treating symptom recurrence in several patients with 
      HIV/CM. This retrospective study aimed to investigate the efficacy and safety of 
      thalidomide in the treatment of symptom recurrence following HIV/CM. METHODS: 
      Patients who were treated with thalidomide for symptom recurrence following 
      HIV/CM were retrospectively included. Clinical outcomes and adverse events were 
      recorded and analyzed. RESULTS: Sixteen patients admitted between July 2018 and 
      September 2020 were included in the analysis. During a median follow-up period of 
      295 (166, 419) days, all patients achieved clinical improvement in a median of 7 
      (4, 20) days. Among them, nine (56%) achieved complete resolution of symptoms at 
      a median of 187 (131, 253) days, including 40% (2/5) of immune reconstitution 
      inflammatory syndrome (IRIS), 50% (3/6) of patients with elevated ICP only, and 
      80% (4/5) of patients with symptoms only. Seven (43%) patients experienced nine 
      episodes of adverse events, but no severe adverse event attributable to 
      thalidomide was observed. None of the patients withdrew from thalidomide due to 
      adverse events. CONCLUSION: Thalidomide appears to be effective and safe in 
      treating different types of symptom recurrence in HIV/CM. This study provides 
      preliminary evidence supporting future randomized clinical trials to further 
      investigate the efficacy and safety of thalidomide in treating symptom recurrence 
      in this population.
CI  - (c) 2023. The Author(s).
FAU - Qi, Tangkai
AU  - Qi T
AUID- ORCID: 0000-0002-3771-2488
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Chen, Fang
AU  - Chen F
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
AD  - Nanchang Ninth Hospital, Nanchang, 330002, Jiangxi, China.
FAU - Ma, Siyue
AU  - Ma S
AD  - School of Nursing, Fudan University, Shanghai, China.
FAU - Zhang, Renfang
AU  - Zhang R
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Liu, Li
AU  - Liu L
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Wang, Zhenyan
AU  - Wang Z
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Tang, Yang
AU  - Tang Y
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Song, Wei
AU  - Song W
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Sun, Jianjun
AU  - Sun J
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Yang, Junyang
AU  - Yang J
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Xu, Shuibao
AU  - Xu S
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Zhao, Bihe
AU  - Zhao B
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Shen, Yinzhong
AU  - Shen Y
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China.
FAU - Chen, Jun
AU  - Chen J
AUID- ORCID: 0000-0002-3850-4875
AD  - Department of Infection and Immunology, Shanghai Public Health Clinical Center, 
      2901 Caolang Road, Shanghai, 201508, China. qtchenjun@163.com.
LA  - eng
GR  - 20MC1920100/Shanghai Science and Technology Committee/
GR  - GWV-10.1-XK02/Shanghai major projects on infectious diseases/
GR  - 2019-72/Shanghai Rising stars of Medical Talent Youth Development Program/
GR  - 2020089/shanghai talent development fund/
PT  - Journal Article
DEP - 20230608
PL  - New Zealand
TA  - Infect Dis Ther
JT  - Infectious diseases and therapy
JID - 101634499
PMC - PMC10281922
OTO - NOTNLM
OT  - Cryptococcal meningitis
OT  - HIV
OT  - Immune reconstitution inflammatory syndrome
OT  - Recurrence of symptom
OT  - Thalidomide
EDAT- 2023/06/08 01:08
MHDA- 2023/06/08 01:09
PMCR- 2023/06/08
CRDT- 2023/06/07 23:36
PHST- 2023/01/31 00:00 [received]
PHST- 2023/05/02 00:00 [accepted]
PHST- 2023/06/08 01:09 [medline]
PHST- 2023/06/08 01:08 [pubmed]
PHST- 2023/06/07 23:36 [entrez]
PHST- 2023/06/08 00:00 [pmc-release]
AID - 10.1007/s40121-023-00817-x [pii]
AID - 817 [pii]
AID - 10.1007/s40121-023-00817-x [doi]
PST - ppublish
SO  - Infect Dis Ther. 2023 Jun;12(6):1667-1675. doi: 10.1007/s40121-023-00817-x. Epub 
      2023 Jun 8.